Dana-Farber Cancer Institute2024 SABCS Highlights

The 2024 San Antonio Breast Cancer Symposium (SABCS) featured significant research presentations from Dana-Farber Cancer Institute clinician-scientists, spanning interventional weight management, targeted therapies, and active monitoring approaches. The international symposium, which drew approximately 10,000 attendees from over 100 countries, showcased advances in experimental biology, prevention strategies, and therapeutic innovations for breast cancer and premalignant breast disease.

Key Points:

• A telephone-based weight loss intervention demonstrated meaningful improvements in metabolic and inflammatory biomarkers linked to cancer recurrence, as presented by Dr. Jennifer Ligibel, highlighting the potential impact of lifestyle modifications on patient outcomes.
• Dr. Antonio Giordano presented new data evaluating a CDK4-selective inhibitor combined with letrozole as first-line treatment for HR+/HER2- metastatic breast cancer, advancing the understanding of targeted therapy combinations.
• The MARGOT phase 2 trial, presented by Dr. Ada Waks, compared the efficacy of margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in early-stage HER2+ breast cancer patients.
• Updated results from the phase 3 OlympiA study, presented by Dr. Judy Garber, reinforced the benefits of olaparib in high-risk, HER2-negative breast cancer patients with germline BRCA1/2 mutations.
• The phase 3 COMET trial results, presented by Dr. Ann Partridge, revealed that patients with low-risk DCIS under active monitoring achieved comparable physical, emotional, and psychological outcomes to those receiving standard treatment.

HCN Medical Memo
The 2024 SABCS presentations demonstrate significant progress in personalized treatment approaches, from lifestyle interventions to targeted therapies, supporting evidence-based decision-making in breast cancer management.

More in Precision Medicine